TRUFFLE-CAPITAL
Truffle Capital:
1. Three leading BioMedTech companies, Founded or Co-Founded and Supported by Truffle Capital since Their Inception, Generate Outstanding Performance in 2020
As of today, Abivax (EPA: ABVX), Carbios (EPA: ALCRB) and Carmat (EPA: ALCAR), are collectively capitalizing €1.3 billion (497, 443 and 379 M€ respectively) and ranking among the best 2020 stock performers listed on Euronext Paris (including Carbios at the 1st position; among the companies capitalizing between €200 million and 2 billion; see table below). These three companies are all developing radical innovations aiming at revolutionizing the medical sector or the protection of the environment.
Here are the latest companies’ breaking news for these three companies:
-
November 19, 2020: Carbios
, founded by Truffle Capital in 2011 develops industrial bioprocesses for the circular economy of plastics, Carbios
made its first 100% recycled plastic bottle from textiles. Based in French region of Auvergne, Carbios
published a major scientific article in Nature
, was able to attract renowned corporate partners (L’Oréal, Michelin, Nestlé Waters, Novozymes, PepsiCo, Suntory Beverage & Food Europe), and is now at the industrial pilot stage.
Link: News/Carbios/First Plastic Bottle from Recycled Textile
Link: News/Carbios/Nature Cover Page
-
December 22, 2020: Abivax
, founded by Truffle Capital in 2013, is developing innovative drugs to treat patients with inflammatory diseases, viral diseases and cancers. Abivax
ABX464 drug candidate was declared a National Covid-19 Research Priority
by the French government for its large international clinical trial, miR-AGE, launched last May with ABX464. This BioTech company already secured €84 million in funding over the year.
Link: News/Abivax/National Covid-19 Research Priority
-
December 23, 2020: Carmat
, co-founded by Truffle Capital, Airbus and Pr Carpentier in 2008, designer and developer of the world's most advanced total artificial heart conceived to provide a therapeutic alternative for patients suffering from end-stage biventricular heart failure, obtained market approval in Europe (CE marking).
Link: News/Carmat/CE Marking
For detailed information regarding these companies, including risk factors, please refer to their respective websites (Carbios : www.carbios.fr ; Abivax : www.abivax.com and Carmat : www.carmatsa.com ).
These companies and their achievements are Truffle Capital's signature as an entrepreneur-investor company : sourcing radical innovations in biotechnology and medical devices from around the world to build leading companies in France and support them towards advanced development stages.
Philippe Pouletty, M.D. co-founder and CEO of Truffle Capital, mentions: “We are proud of these three French companies that would not have existed without Truffle. Contributing to saving lives or protecting our planet, thanks to exceptional scientific research and technologies and to international management teams, fosters the emergence of future World leaders in France, while generating a very good return on investment for Truffle Capital’s funds. We intend to amplify our efforts with our new BioMedTech and Medeor funds, to benefit patients around the world and our investors.”
2020 Stock Performance Ranking of Euronext Paris listed BioMedTech Companies, with a Market Capitalization between 200 million and 2 billion euros on 01/01/2020 |
Ranking |
Company |
2020 Stock Performance (%) |
Market Capitalization
|
1 |
Carbios |
318% |
443 |
2 |
AB Sciences |
276% |
752 |
3 |
Inventiva |
219% |
572 |
4 |
Valneva |
202% |
826 |
5 |
Gensight Biologics |
187% |
304 |
6 |
Cellectis |
56% |
1098 |
7 |
Abivax |
53% |
497 |
8 |
Carmat |
47% |
379 |
9 |
Innate Pharma |
-42% |
291 |
10 |
DBV Technologies |
-78% |
545 |
Index |
2020 Performance |
CAC 40 |
-7% |
Next Biotech |
-6% |
Sources: Price per share variation (%) from 12/31/2019 to 12/31/2020; market capitalization on 01/22/2021. Companies in the diagnostics sector or with market capitalizations less than 200 million euros or over 2 billion euros as of January 1, 2020 were excluded. This ranking was established based on Euronext data.
2. New BioMedTech Companies created by Truffle Capital in Major Healthcare Sectors
Truffle continues to create and support future BioMedTech leaders aiming to treat life threatening diseases. Truffle Early-Stage BioMedTech Funds, which closed at the end of 2019, have already enabled the financing of 8 BioMedTech companies built on promising radical innovations.
- Affluent Medical (Aix en Provence) is developing four minimally invasive medical devices to treat cardiac, vascular and urologic diseases, which are already at an advanced clinical development stage;
- Artedrone (Paris) is aiming to design revolutionary autonomous microrobots allowing interventional radiologists to treat or prevent cerebrovascular accidents without using catheters;
- Bariatek (Paris) is developing a minimally invasive medical device to treat obesity;
- Caranx Medical (Nice) is developing autonomous surgical robots, for vascular and abdominal surgery;
- Diaccurate (Paris) is developing novel anti-cancer and anti-viral drugs based on breakthrough immuno-oncology mechanisms;
- HoliStick Medical (Paris) is developing a medical device to close pathological holes between the right and left heart (PFO) in order to prevent strokes;
- PKMed (Lyon), is developing biocompatible 3D implants to enable local drug delivery or to promote the genesis of functional tissues and organs following cell therapy;
- Skinosive (Marseille) is developing bioadhesive technologies to increase the effectiveness and safety of UV filters and other dermato-cosmetic compounds.
3. MEDEOR, Truffle New Late-Stage BioMedTech Fund, expects a first closing before summer
Truffle new MEDEOR Fund aims to complement Truffle's BioMedTech financing tools for BioMedTech companies, from inception to commercial stages. It has a clear industrial objective: invest at least €600 million in future BioMedTech world leaders developing advanced-stage medical devices (pre-commercial or commercial stage, for 70%) or innovative drugs (phase II & III clinical studies, for 30%). MEDEOR will always be lead investor and major proactive shareholder and board member, to build in France technological leaders that will revolutionize surgery and medicine. French institutional investors and French government granted MEDEOR the “Tibi” label, a French government initiative to encourage LP’s to invest in the best funds.
Thanks to MEDEOR, Truffle Capital intends to continue to lead French BioTech and MedTech companies towards commercial and international medical success.
4. Truffle : a High Performance business model launched twenty years ago
Founded in 2001, Truffle Capital is an independent European Venture Capital firm focused on radical innovations in Life Sciences (MedTech and BioTech) and breakthrough technologies in the IT sector (FinTech and InsurTech). Truffle Capital's mission is to support the founding and development of young innovative companies capable of becoming tomorrow’s leaders. Chaired by Patrick Kron and managed by Dr. Philippe Pouletty and Bernard-Louis Roques, Co-Founders and Chief Executive Officers, Truffle Capital has raised more than €1.1 billion since its creation and has supported several dozens of companies in the life sciences and digital technology sectors. In 2019, Truffle Capital announced the raising of nearly €400 million for its early-stage institutional funds, including €250 million dedicated to BioMedTech.
2020 was marked by the launch of new innovative projects in its two areas of expertise (BioMedTech and FinTech/InsurTech) and by very significant advances in the field of Biotechnology and Medical Devices.
******
For more information: www.truffle.com — Twitter: @trufflecapital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005496/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Confirms $MBG Token TGE Set for July 22, 202512.7.2025 11:14:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250712404220/en/ MultiBank Group has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This milestone will mark the full activation of the $MBG Token on the blockchain, enabling holders to view and manage their balances across supported platforms. Following the token minting, users will be able to trade $MBG via MultiBank.io, the Group’s regulated crypto exchange and Uniswap, the world’s leading decentralized platform. The $MBG Token has garnered global attention for its rare combination of real-world utility, institutional backing, and strong deflationary mechanics. It is underpinned by $29 billi
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics11.7.2025 14:00:00 CEST | Press release
Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711152688/en/ As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hi
$MBG Token Pre-Sale Set for July 15 — Only 7 Million Tokens Available at $0.3511.7.2025 10:17:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has confirmed that its highly anticipated $MBG Token pre-sale will go live on July 15, with demand expected to be intense. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711737311/en/ With only 7 million $MBG tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. With only 7 million tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. Early participants can join simultaneously on MultiBank.io, the Group’s regulated crypto exchange, and Uniswap, the world’s leading decentralized platform. Supported by $29 billion in real assets and powered by over $35 billion in daily turnover, $MBG is engineered
Live Story Raises €2.7 Million to Revolutionize the Digital Experience11.7.2025 10:05:00 CEST | Press release
With a round led by Vertis, the next-generation CMS platform accelerates its focus onAI, performance, and European expansion. Target: surpass €10M in recurring revenueby 2027. Live Story, the tech company founded by Stefano Mocellini, has closed a €2.7 million seed round led by Vertis, one of Italy’s leading early-growth venture capital firms. The funding will support the company’s international expansion and technological development, with a clear goal: to exceed €10 million in annual recurringrevenue by 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711335560/en/ “We invested in Live Story because it addresses one of the major inefficiencies in digital commerce: the slow and rigid management of visual and narrative content,” says Alessandro Pontari, Partner at Vertis SGR. “The platform helps brands drastically reduce their time-to-market through a visual CMS that integrates seamlessly with any tech stack. In a wor
With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 09:00:00 CEST | Press release
Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom